And the Award for Most Inspiring Lecture at ASH Goes to…
Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.
Should Progression-Free Survival Be the Primary End Point for Registration of Oncology Drugs?
If the title is correct, an article in the November 10 issue of the Journal of Clinical Oncology shows that many randomized trials in oncology are improperly designed and many drugs used in oncology have been approved based on the wrong end point.
The End of Conventional Chemotherapy for Urothelial Cancer
According to John M. Burke, MD, it is hard to imagine that results presented at ESMO in the urothelial cancer space will not lead to the complete replacement of conventional chemotherapy as the standard first-line treatment.
PERSEUS and ELEVATE-TN Trials Are Potential Game-Changers in MM and CLL
John M. Burke, MD, discusses the 2 phase 3 trials presented at the 2023 ASH Annual Meeting that have potential to be practice changing for patients with multiple myeloma and chronic lymphocytic leukemia.
Debate Over the Inflation Reduction Act Is Heating Up
In this article, John M. Burke, MD, discusses the high prices of prescription drugs and the new law that allows the government to negotiate drug prices with manufacturers.
BTK Inhibitors Gain New Ground in Follicular Lymphoma
John M. Burke, MD, discusses how Bruton tyrosine kinase inhibitors have demonstrated unexpected promise in treating follicular lymphoma, challenging previous assumptions in the field of oncology.
Immune Checkpoint Inhibitors Further Refine Hodgkin Lymphoma Regimens
During the plenary session of the 2023 American Society of Clinical Oncology Annual Meeting, we learned that BV-AVD’s reign at the top may be short lived.
Can Artificial Intelligence Change the Practice of Oncology?
John M. Burke, MD, turns to ChatGPT to uncover what artificial intelligence may do for hematologists/oncologists.
Circulating Tumor DNA Measurement in Lymphoma One of the Big Stories From ASH
John M. Burke, MD, highlights progress in the field of hematology and oncology presented at the 64th American Society of Hematology Annual Meeting and Exposition.
Oncology Societies Recognize and Address Burnout During Conferences
According to John M. Burke, MD, significant attention has been paid in recent years to the problem of physician burnout and as oncologists continue to care for patients, it important to also care for themselves.
Bispecifics Show Promise Against Hematologic Malignancies
Additional data emerged demonstrating the value of blinatumomab not only in patients with relapsed acute lymphoblastic leukemia but also in those with detectable minimal residual disease.
Innovative Therapies, Care Equity Highlight 2022 ASCO Annual Meeting
After a meeting like the 2022 ASCO Annual Meeting, one cannot help but be reinvigorated to continue advancing cancer care and feel optimistic about the future of oncology, says John M. Burke, MD.
Collaborative Efforts Push the Boundaries of Immunotherapy
In this month's 10-year anniversary issue of Targeted Therapies in
Oncology™, we feature an article on the evolution of immunotherapy
approaches in oncology over the past decade.
Novel Testing Modalities Are Poised to Improve Diagnosis and Prognosis
Improving our diagnostic and prognostic testing capabilities is one of the most important and exciting ways to improve how we care for patients with cancer, according to John M. Burke, MD.
Barriers to Access for COVID-19 Treatments Put Patients With Cancer at Risk
Amid the surge of the omicron variant, the FDA issued an emergency use authorization for the orally administered antiviral combination, which can reduce the rate hospitalization or death by 87% compared with no treatment.
ADC, CAR T-Cell Therapy Push DLBCL Into Spotlight at ASH Conference
Clinical trial findings presented during the ASH annual meeting have the potential to change the management of diffuse large B-cell lymphoma, according to John M. Burke, MD.
Next Steps Using Anti-CD19 Therapies in DLBCL
The future of combined treatment approaches with anti-CD19 therapies for diffuse large B-cell lymphoma.
R/R DLBCL: Educating Patients About CAR T Cells
Suggestions to hematologist-oncologists when talking to patients with relapsed/refractory diffuse large B-cell lymphoma about the potential benefits of CAR T-cell therapy and toxicities.
CAR T Cells in R/R DLBCL
Recommendations to increase the uptake of CAR T-cell therapies into clinical practice when managing patients with relapsed/refractory diffuse large B-cell lymphoma.
Anti-CD19 Therapy for DLBCL: Treatment Selection
Variables that are likely to impact the use of loncastuximab vs a combination approach with tafasitamab and lenalidomide to treat relapsed/refractory diffuse large B-cell lymphoma.
Loncastuximab for R/R DLBCL
An overview of the LOTIS-1 clinical trial and the rationale for the accelerated approval of loncastuximab for relapsed/refractory diffuse large B-cell lymphoma.
Anti-CD19 Targeted Therapy for DLBCL: Safety and Efficacy
Recommendations for managing patients with diffuse large B-cell lymphoma on tafasitamab.
Novel Frontline Approaches Under Study for R/R DLBCL
An overview of potential strategies being explored to improve frontline therapy with R-CHOP for patients with relapsed/refractory diffuse large B-cell lymphoma.
Frontline Therapy for R/R DLBCL: TAFA/LEN/R-CHOP
Drs John M. Burke and Marin F. Xavier consider the potential utilization of tafasitamab plus lenalidomide plus R-CHOP chemotherapy vs R-CHOP chemotherapy alone as relapsed/refractory diffuse large B-cell lymphoma treatment.
Individualized Therapy for Unfit Patients With R/R DLBCL
Implications for treating unfit patients with relapsed/refractory diffuse large B-cell lymphoma with chemotherapy or the combination of tafasitamab and lenalidomide based on patient characteristics and the L-MIND trial.
R/R DLBCL: Treating Fit Patients Who Are Transplant Eligible
Recommendations for approaching patients with relapsed/refractory diffuse large B-cell lymphoma with newer targeted treatment approaches as frontline therapy vs referral for transplant.
CD19-Targeted Therapy for DLBCL
The rationale for sequencing therapy with CD19-targeted agents when managing patients with various subtypes of diffuse large B-cell lymphoma.
DLBCL: Prognosis and Goals of Therapy
Variables that impact a patient with diffuse large B-cell lymphoma, and prognosis and strategies for counseling patients on goals of therapy.
DLBCL: Approaches for Monitoring Frontline Treatment Response
Debates regarding the proper timing for repeat scans, interval CT testing, and surveillance imaging on patients with diffuse large B-cell lymphoma following frontline therapy.
DLBCL Risk Status and Frontline Treatment Decisions
The differences between frontline treatment strategies for early stage vs double- or triple-hit diffuse large B-cell lymphoma.
2 Commerce Drive Cranbury, NJ 08512